Atea Pharma Insider Adds Shares; Granted RSUs & Options at $3.25
Rhea-AI Filing Summary
Form 4 highlights for Atea Pharmaceuticals (AVIR): Director Jerome M. Adams reported several equity transactions on 20 June 2025.
- Common shares acquired: 29,600 shares were received upon conversion of previously vested restricted stock units (RSUs) at an effective price of $0.00 (code M). Adams now holds 62,750 AVIR shares directly.
- New equity awards granted:
- RSUs: 29,600 units granted (code A). They vest in a single installment on the earlier of the next annual meeting or the first anniversary of grant, subject to continued service.
- Stock options: 41,200 options granted with a $3.25 exercise price, expiring 19 June 2035. Vest monthly over 12 months, fully vested after one year.
- No derivative securities were sold; 29,600 RSUs were converted and the related derivative position is now zero.
Overall, the director increased his direct equity stake and received additional incentive-based awards, signaling continued alignment with shareholder interests.
Positive
- Director increased direct share ownership by 29,600 shares, bringing total holdings to 62,750, a potential show of confidence.
- Granted 41,200 options at $3.25, providing long-term incentive aligned with shareholder value creation.
- Additional 29,600 RSUs granted that vest within a year, further tying compensation to performance.
Negative
- None.
Insights
TL;DR – Director adds 29.6k shares, receives new 29.6k RSUs and 41.2k options at $3.25, boosting alignment.
The filing shows insider net share accumulation, not disposal. The zero-cost conversion of vested RSUs increased direct ownership to 62,750 shares, while newly granted RSUs and options extend equity exposure through 2035. Although the share count is modest versus Atea’s 83 million basic shares, insider buying—especially by a director—may be interpreted as a confidence signal. The $3.25 strike sits well below the 52-week high near $7 (as of recent trading), giving material upside leverage if the pipeline delivers. No negative governance flags appear; standard one-year vesting aligns with industry norms and encourages retention. Impact on float dilution is de minimis at <0.1%.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Restricted Stock Units | 29,600 | $0.00 | -- |
| Grant/Award | Stock Option (Right to Buy) | 41,200 | $0.00 | -- |
| Exercise | Restricted Stock Units | 29,600 | $0.00 | -- |
| Exercise | Common Stock | 29,600 | $0.00 | -- |
Footnotes (1)
- Restricted stock units convert into common stock on a one-for-one basis. The restricted stock units vest in a single installment on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders occurring after the date of grant or (ii) the first anniversary of the date of grant, in each case, subject to the Reporting Person's continued service through the applicable vesting date. The option vests and becomes exercisable in twelve (12) substantially equal monthly installments following June 20, 2025, such that the option shall be fully vested on the first anniversary of the date of grant, subject to the Reporting Person's continued service through each such vesting date. The restricted stock units vested in full on June 20, 2025.
